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Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC), an essential
component of the inﬂammasome complex, is frequently silenced by epigenetic methylation in many
tumor cells. Here, we demonstrate that restoration of ASC expression in human colorectal cancer DLD-
1 cells, in which ASC is silenced by aberrant methylation, potentiated cell death mediated by DNA dam-
aging agent. Contrarily, ASC knockdown in HT-29 cells rendered cells less susceptible to etoposide toxic-
ity. The increased susceptibility of ASC-expressing DLD-1 cells to genotoxic stress was independent of
inﬂammasome or caspase activation, but partially dependent on mitochondrial ROS production and
JNK activation. Thus, our data suggest that ASC expression in cancer cells is an important factor in deter-
mining their susceptibility to chemotherapy.
 2013 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Apoptosis-associated speck-like protein containing a caspase
recruitment domain (ASC) is a bipartite protein consisting of two
death domains, an N-terminal pyrin domain (PYD) and a C-termi-
nal caspase recruitment domain (CARD) [1]. A number of proteins
containing the death-fold domain have been widely shown to play
a pivotal role in apoptotic cell death and inﬂammation [2]. In par-
ticular, accumulating reports have recently demonstrated that ASC
is an essential adaptor molecule of the inﬂammasome complex,
which mediates the conversion of procaspase-1 to active cas-
pase-1 and the subsequent maturation of interleukin-1 beta (IL-
1b) and IL-18, the key proinﬂammatory cytokines [3].
Upon stimulation of the macrophages or dendritic cells by path-
ogen-associated molecular pattern (PAMP) or danger-associated
molecular pattern (DAMP), PYD-containing pattern-recognition
receptors such as the NOD-like receptor family, pyrin domain con-
taining-3 protein (NLRP3) or absent in melanoma 2 (AIM2) associ-
ate with ASC through PYD homotypic interactions [4]. ASC then
recruits procaspase-1 through CARD–CARD interaction to form aninﬂammasome complex leading to the activation of caspase-1.
The PAMP- or DAMP-triggered assembly of the inﬂammasome in-
duces not only the maturation of the inﬂammation-initiating pro-
inﬂammatory cytokines IL-1b and IL-18 but also caspase-1-
dependent pyroptotic cell death depending on the cell type [5,6].
ASC was originally identiﬁed in human leukemia cells based on
its ability to form speck-like aggregates and trigger apoptosis in re-
sponse to retinoic acid or anti-tumor drugs [7]. Interestingly, ASC
was also identiﬁed as a downstream target of methylation-induced
gene silencing by DNA methyltransferase and thus initially named
as ‘target of methylation-induced silencing 1 (TMS1)’ [8]. ASC is in-
deed epigenetically silenced by aberrant methylation of its CpG is-
lands in many tumor cells; particularly, it has been reported to be
silenced in 40% of primary breast tumors [8–10]. This observation
suggests that ASC might be a potential tumor suppressor gene, and
its silencing might contribute to carcinogenesis in some tumors.
The cell death-promoting role of ASC has been suggested in a
number of reports; however, the underlying mechanism of apopto-
sis induction is quite controversial depending on the cell type. The
most intriguing involvement of ASC in cell death is the mediation
of caspase-1-dependent pyroptosis through inﬂammasome forma-
tion [5]; however, pyroptosis is known to mainly occur in innate
immune cells to clear intracellular pathogens [11]. In addition to
pyroptosis, overexpression of ASC was initially shown to induce
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By contrast, many other reports have also demonstrated that ASC
triggers caspase-8-dependent apoptotic cell death [13–15]. In hu-
manmammary epithelial cells, DNA damage or loss of extracellular
matrix contact induced ASC expression leading to apoptosis
[15,16], indicating that ASC is deﬁnitively associated with the sup-
pression of cancer progression.
Here, we demonstrated that ASC expression in colorectal cancer
cells clearly augments the cell death caused by DNA damaging
agents. Contrary to previous speculations, we found that the in-
creased susceptibility of ASC-expressing cells to genotoxic stress
is not caused by caspase activation, but can be partially attributed
to the production of mitochondrial reactive oxygen species (ROS)
and the activation of c-jun kinase (JNK) mitogen-activated protein
kinase (MAPK) signaling pathway.
2. Materials and methods
2.1. Cell culture
DLD-1 cells were purchased from Korean Cell Line Bank and maintained in
DMEM supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin
and streptomycin. A549, NCI-1650, HCC827, PC-3, Du145, LNCaP, MDA-MB231,
SK-BR3, MCF-7, HCT116, HT-29, and THP-1 cells were purchased from the American
Type Culture Collection (ATCC). THP-1 cells were grown in RPMI 1640 medium sup-
plemented with 10% FBS, 2 mM glutamine, 10 mM HEPES, 1 mM sodium pyruvate,
0.05 mM 2-mercaptoethanol, and 100 U/ml penicillin and streptomycin. Wild-type
or ASC-deﬁcient immortalized mouse bone marrow-derived macrophages were
kindly gifted by Dr. Fitzgerald (University of Massachusetts) and cultured in DMEM
supplemented with 10% FBS, 5% L929 cell supplements, and 100 U/ml penicillin and
streptomycin. To generate ASC stably-expressing cells, DLD-1 cells were transfected
with pMSCV-puromycin with or without the pcDNA3-T7-ASC construct using Lipo-
fectamine 2000 (Invitrogen) according to the manufacturer’s protocol. Puromycin-
resistant clones were then selected during 3–4 weeks of culture and screened for
ASC expression.
2.2. Reagents
Etoposide, camptothecin, doxorubicin, 5-aza-20-deoxycytidine (5-AD), lipopoly-
saccharide (LPS), nigericin, poly (dA:dT), cycloheximide (CHX), and N-acetyl-L-
cysteine (NAC) were purchased from Sigma. Z-VAD(OMe)-ﬂuoromethylketone
(zVAD-fmk) and acetyl-YVAD-chloromethylketone (YVAD-cmk) were obtained
from Bachem. The p38 MAPK inhibitor SB203580, JNK inhibitor SP600125, and
necrostatin-1 were from Calbiochem. Recombinant human tumor necrosis factor
a (TNF-a) was purchased from R&D Systems. ASC-speciﬁc small interfering RNA
(siRNA) and negative control siRNA were from Invitrogen (Stealth RNAi).
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total cellular RNA was isolated from DLD-1 cells using the PureLinkTM RNA Mini
Kit (Invitrogen) and reverse transcribed using the SuperScript cDNA Synthesis Kit
(Invitrogen). Template DNA was then ampliﬁed by PCR using the following primers:
50-TGG GCC TGC AGG AGA TG-30 and 50-ATT TGG TGG GAT TGC CAG-30 for ASC, and
50-CCT TCC TGG GCA TGG AGT CCT G-30 and 50-GGA GCA ATG ATC TTG ATC TTC-30
for b-actin.
2.4. Immunoblot assay
Cells were lysed in 20 mM HEPES (pH 7.5) buffer containing 0.5% Nonidet P40,
50 mMKCl, 150 mMNaCl, 1.5 mMMgCl2, 1 mM EGTA, and protease inhibitors. Solu-
ble lysateswere subjected to SDS–PAGE, transferred onto PVDFmembranes, and then
immunoblottedwith the appropriate antibodies. To determine inﬂammasome activ-
ity, culture supernatants were precipitated as described previously [17]. Anti-ASC,
anti-human caspase-1 (p10), and anti-b-actin antibodies were from Santa Cruz Bio-
technology. Anti-human IL-1b, anti-caspase-3, anti-poly(ADP-ribose) polymerase
(PARP), anti-phospho JNK, and anti-phospho-c-Jun antibodies were from Cell Signal-
ing Technology. Anti-JNK antibody was from BD Biosciences. Anti-NLRP3 antibody
was purchased from Alexis Biochemicals. Anti-HMGB1 antibody was from Abcam.
2.5. Cell death assay
Cell death was determined by the extracellular release of lactate dehydrogenase
(LDH) using a CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit (Promega). LDH
release was calculated as [Ae/(Ae + Ai)]  100, where Ae and Ai indicate the levels of
extracellular and intracellular LDH, respectively. Cell survival was determined bymeasuring the conversion of methyl-thiazolyldiphenyl tetrazolium bromide
(MTT; Sigma) into formazan at 570 nm. The type of cell death was determined using
a Fluorescein Isothiocyanate (FITC) Annexin V Apoptosis Detection Kit (BD Biosci-
ences) as described previously [18]. In brief, attached cells, after appropriate treat-
ment, were washed with phosphate-buffered saline (PBS) and stained with Annexin
V-FITC and propidium iodide (PI) in binding buffer (10 mM HEPES, 140 mM NaCl,
2.5 mM CaCl2, pH 7.4) for 10 min. Following trypsinization, the cells were washed
two times with PBS and resuspended in binding buffer (5  105 cells/ml). Simulta-
neously, ﬂoating cells, after appropriate treatment, were resuspended in binding
buffer and stained with Annexin V-FITC for 10 min. After washing with binding buf-
fer, the ﬂoating cells were stained with PI and resuspended in binding buffer. Fluo-
rescence of the mixture of attached and ﬂoating cells was then analyzed by ﬂow
cytometry (BD, FACSCaliburTM). Extracellular releases of ATP were measured by
ATP determination kit (Invitrogen) according to the manufacturer’s protocol.
2.6. Immunoﬂuorescence assay
Cells were grown on a cover slip and treated with etoposide for 24 h. After
washing with PBS, the cells were ﬁxed with 4% paraformaldehyde and permeabili-
zed with 0.2% Triton X-100. Subsequently, cover slips were blocked with 4% normal
goat serum and incubated with an anti-ASC antibody (Santa Cruz Biotechnology),
followed by incubation with the Alexa Fluor 488 anti-rabbit IgG antibody (Invitro-
gen). The cell samples were mounted using the ProLong Gold reagent (Invitrogen)
containing 40 , 6-diamidino-2-phenylindole (DAPI) as the nuclei stain and examined
under a confocal microscope (Olympus, FluoView FV1000).
2.7. Mitochondrial ROS production
Cells, after appropriate treatment, were trypsinized and resuspended in Hank’s
balanced salt solution containing calcium and magnesium. The MitoSox (Invitro-
gen) stock solution was then added to the cells at a ﬁnal concentration of 2.5 lM
and incubated at 37 C for 10 min. Cells were washed three times, and the ﬂuores-
cence was monitored by ﬂow cytometry.
2.8. Knockdown of ASC by siRNA
HT-29 cells were transfected with a control non-targeting siRNA or with an
ASC-targeting siRNA (50 nM) using Lipofectamine 2000 according to the manufac-
turer’s instructions. After 48 h of transfection, cells were washed and treated with
chemotherapeutic agents.
2.9. Statistical analysis
All values were expressed as mean ± standard deviation (SD) of n observations.
Data were statistically analyzed by using an unpaired Student’s t-test. p-values of
0.05 or less were considered signiﬁcant.
3. Results
3.1. ASC is epigenetically silenced by aberrant methylation in human
colorectal cancer DLD-1 cells
To explore the molecular function of ASC in cancer cells, we ﬁrst
determined ASC expression in twelve cancer cell lines derived from
various tissues. Two-thirds of the tumor cell lines tested did not
express ASC, indicating that ASC is frequently silenced in tumor
cells (Fig. 1A). It has indeed been reported that many tumor cells,
such as Du145, LNCaP, MDA-MB231, HCT 116, and DLD-1, showed
complete methylation of the ASC promoter region [19–21]. By con-
trast, both MCF-7 and HT-29 cells, in which the ASC promoter is
rarely methylated according to previous reports [20,21], exhibited
robust expression of ASC (Fig. 1A), suggesting that ASC expression
is primarily regulated by epigenetic methylation-induced silencing
in cancer cells.
In innate immune cells, ASC plays a crucial role in assembling
the inﬂammasome complex, leading to secretion of proinﬂamma-
tory cytokines [22]. Because chronic inﬂammation is closely linked
to the initiation of colorectal cancer, we decided to investigate the
role of ASC in colorectal cancer DLD-1 cells, in which ASC is epige-
netically silenced by methylation [9,21]. To examine whether ASC
expression could be restored by demethylation, we treated DLD-1
cells with 5-AD, a DNAmethyltransferase inhibitor. ASC expression
was not observed in the resting state of DLD-1 cells, but was
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Fig. 1. ASC expression sensitizes human colorectal cancer DLD-1 cells to DNA damaging agents. (A) Cellular lysates from various cancer cell lines or mouse bone marrow-
derived macrophages (BMDMs) were immunoblotted with anti-ASC or anti-b-actin antibodies. (B) ASC expression in DLD-1 cells with or without 5-AD priming (2 lM, 4 days)
was determined by RT-PCR or western blot analysis. (C) DLD-1 cells with or without 5-AD-priming (2 lM, 48 h) were treated with etoposide (50 lM) or doxorubicin (1 lM)
for additional 38 h. Cell survival rate was determined by MTT assay. Asterisks indicate signiﬁcant differences between unprimed and 5-AD-primed cells (n = 3, p < 0.05). (D)
Western blotting of the lysates of DLD-1-puro or DLD-1-ASC stable cells. (E) DLD-1-puro or DLD-1-ASC cells were treated with etoposide or doxorubicin at the indicated
concentration for 30 h. Culture supernatants and cellular lysates were assayed to determine extracellular LDH release. Asterisks indicate signiﬁcant differences compared to
DLD-1-puro cells (left panel, n = 3, p < 0.01; p < 0.005; p < 0.0005; right panel, n = 3, p < 0.005; p < 0.001).
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and Western blot analysis (Fig. 1B). These results suggest that ASC
expression in DLD-1 cells is mainly suppressed by epigenetic
methylation of its promoter region.
3.2. ASC expression sensitizes DLD-1 cells to DNA damaging agents
To examine the tumor-suppressive function of ASC in DLD-1
cells, we ﬁrst treated unprimed or 5-AD-primed DLD-1 cells with
the chemotherapeutic drugs, etoposide and doxorubicin, which
are known to induce DNA damage leading to cell death [23]. 5-
AD-primed DLD-1 cells showed a signiﬁcant decrease in cell sur-
vival upon treatment with DNA damaging agents, compared with
unprimed DLD-1 cells, as revealed by the MTT assay (Fig. 1C). In
addition, the DNA damaging agents caused more severe cytotoxic-
ity to 5-AD-primed DLD-1 cells than to unprimed DLD-1 cells, as
determined by extracellular LDH release (Supplementary Fig. 1A).
These results indicate that demethylation-induced ASC expression
renders DLD-1 cells more susceptible to genotoxic stress.
In addition to ASC, demethylation by 5-AD treatment is able to
induce the expression of other aberrantly methylated genes at
their CpG islands in DLD-1 cells. Indeed, it has been previously re-
ported that several genes such as LKB1 and DKK-1 are hypermethy-
lated in DLD-1 cells [24,25]. To exclude the possibility that
expression of other epigenetically silenced genes via demethyla-
tion can affect the susceptibility of DLD-1 cells to genotoxic stress,
we generated DLD-1 cells stably expressing ASC (Fig. 1D). We then
determined the susceptibility of both the control DLD-1-puro and
the DLD-1-ASC cells to DNA damaging agents. Cell death was sig-
niﬁcantly higher in the DLD-1-ASC cells than that in the control
DLD-1-puro cells when treated with etoposide, doxorubicin, or
camptothecin (Fig. 1E and Supplementary Fig. 1B).3.3. Decreased ASC expression attenuates cell death caused by DNA
damaging agents
To verify the above-mentioned observation that ASC expression
sensitizes colorectal cancer cells to DNA damaging agents, we
knockdowned ASC expression in human colorectal cancer HT-29
cells, which express ASC due to unmethylation of the ASC promoter
[21]. ASC expression in HT-29 cells was markedly decreased by
transfection with a siRNA speciﬁc to ASC (Fig. 2A). Etoposide in-
duced a dose-dependent cell death in ASC-expressing HT-29 cells,
but not in ASC-knockdowned cells (Fig. 2A). In addition, both cas-
pase-3 and PARP cleavage were attenuated in ASC-knockdowned
HT29 cells (Fig. 2A).
To further examine whether ASC is critical for genotoxic stress-
induced cell death, cells other than cancer cells (wild-type and
ASC-deﬁcient mouse bone marrow-derived macrophages) were
treated with DNA damaging agents. As observed in DLD-1 cells,
etoposide-, camptothecin-, and doxorubicin-induced cell death
was signiﬁcantly suppressed in ASC-deﬁcient macrophages com-
pared with that in ASC-expressing wild-type cells (Fig. 2B and Sup-
plementary Fig. 1C). These results collectively demonstrate that
ASC expression is an important factor for genotoxic stress-induced
cell death of colorectal cancer cells and macrophages.
3.4. Inﬂammasome signaling is not required for the genotoxic stress-
induced cell death of ASC-expressing DLD-1 cells
One recent report proposed that chemotherapeutic agents such
as doxorubicin and daunorubicin induce NLRP3 inﬂammasome
activation in bone marrow-derived macrophages [26]. To under-
stand whether inﬂammasome signaling, which is responsible for
caspase-1-dependent pyroptotic cell death, is involved in DNA
A B
Fig. 2. Decreased ASC expression attenuates DNA damage-induced HT-29 or macrophage cell death. (A) HT-29 cells were transfected with si-control or si-ASC RNA (50 nM),
and after 48 h of transfection, cells were incubated with etoposide as indicated for 30 h and assayed for LDH release. Cellular lysates were immunoblotted with the indicated
antibodies. Asterisk indicates signiﬁcant difference compared to si-ASC-transfected group (n = 3, p < 0.001). (B) Wild-type or ASC-deﬁcient BMDMs were incubated with
etoposide for 5 h (left panel), and with etoposide (2 lM) or doxorubicin (0.5 lM) for 24 h (right panel). Asterisks indicate signiﬁcant differences compared to ASC-deﬁcient
cells (left panel, n = 3, p < 0.001; right panel, n = 3, p < 0.0005).
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examined in DLD-1 cells after treatment of DNA damaging agents.
Although DLD-1 cells express procaspase-1, none of the DNA dam-
aging agents tested induced caspase-1 activation in DLD-1-puro
and DLD-1-ASC cells, as determined by extracellular secretion of
active caspase-1 (Fig. 3A). However, considering that these DNA
damaging agents deﬁnitely induced cell death in the present study,
particularly in DLD-1-ASC cells, we speculate that caspase-1 or
inﬂammasome activity may not be required for ASC-mediated cell
death induced by genotoxic stress.
To further examine whether the activation of the inﬂamma-
some could promote colorectal cancer cell death, ASC-deﬁcient or
ASC-expressing DLD-1 cells were treated with known inﬂamma-
some stimulators. As shown in Fig. 3B, LPS plus nigericin, an acti-
vator of the NLRP3 inﬂammasome, had no effect on the
activation of the inﬂammasome in DLD-1 cells, as determined by
the secretion of active caspase-1 and IL-1b. Similarly, transfection
of poly (dA:dT), which activates AIM2 inﬂammasome [17], failed
to induce caspase-1 or IL-1b activation in DLD-1 cells. In contrast,
LPS plus nigericin as well as poly (dA:dT) promoted robust cas-
pase-1 activation and subsequent secretion of active IL-1b in phor-
bol 12-myristate 13-acetate (PMA)-primed THP-1 cells, which is a
monocytic leukemia cell line (Fig. 3B). Moreover, the activation of
the NLRP3 or AIM2 inﬂammasome triggered substantial cell death
in THP-1 cells, but not in DLD-1 cells (Fig. 3B).
ASC oligomerization is a unique feature of inﬂammasome acti-
vation and pyroptotic cell death [5,27]. ASC is also reported to form
speck-like structures in human leukemia cell lines upon stimula-
tion with chemotherapeutic agents [7]. However, ASC oligomeriza-
tion was not obvious in DLD-1-ASC cells treated with etoposide
(Fig. 3C). These results collectively indicate that ASC-mediated
inﬂammasome formation is not required for colorectal cancer cell
death that occurs in response to genotoxic stress.3.5. Etoposide-induced cell death of ASC-expressing DLD-1 cells is
caspase-independent
To gain a molecular insight into the type of cell death induced
by genotoxic stress, we performed annexin V and PI staining ofthe etoposide-treated and control DLD-1 cells, followed by ﬂow
cytometric analysis of the cells. Etoposide treatment increased an-
nexin V-positive and PI-positive cell populations, which represent
both apoptotic and necrotic cell death, more prominently in DLD-
1-ASC cells (48.7%) than in DLD-1-puro cells (15.67%, Fig. 4A).
However, the population of annexin V-positive and PI-negative
cells, a characteristic of apoptotic cell death, was relatively very
scarce in DLD-1-ASC cells. We thus inferred that etoposide-induced
cell death in DLD-1-ASC cells might be necrotic rather than apop-
totic (Fig. 4A).
Next, to examine whether caspase signaling pathway, a crucial
player in apoptotic cell death, is implicated in etoposide-induced
cell death of ASC-expressing DLD-1 cells, the effect of caspase inhi-
bition by zVAD-fmk, a cell permeable pan-caspase inhibitor, and
Ac-YVAD-cmk, a selective inhibitor of caspase-1, was examined.
Remarkably, etoposide cytotoxicity in 5-AD-primed DLD-1 cells
was unaffected by zVAD or YVAD pretreatment (Fig. 4B, left panel),
indicating that caspase signaling pathways are dispensable for eto-
poside-induced cell death of ASC-expressing DLD-1 cells. In sup-
port of these results, both caspase inhibitors failed to prevent cell
death from etoposide cytotoxicity in DLD-1-ASC stable cells
(Fig. 4B, right panel).
To conﬁrm the caspase-independent cell death by etoposide,
the effect of caspase inhibition was also tested in ASC-expressing
HT-29 cells, well-studied as a caspase-independent cell death
model [28]. Interestingly, inhibition of caspase activity by zVAD
completely blocked caspase-3 and PARP processing (Fig. 4C, lower
panel), but did not prevent etoposide-promoted cell death (Fig. 4C,
upper panel). These results veriﬁed our speculation that etoposide
could trigger caspase-independent cell death in ASC-expressing
cells. We, then, stimulated HT-29 cells with TNF-a plus cyclohexi-
mide (TC), which is known to induce caspase-8-dependent apopto-
sis. The presence of zVAD completely suppressed caspase-3 and
PARP cleavage in HT-29 cells upon stimulation with TC (Fig. 4C,
lower panel, 6th lane), but zVAD did not attenuate TC-induced cell
death (Fig. 4C, upper panel, 6th lane). It has been already demon-
strated that the inhibition of caspase activity by zVAD in the pres-
ence of TC treatment can trigger receptor interacting protein 3
(RIP3)-dependent necrotic cell death in RIP3-expressing cells,
such as HT-29 [29]. In this regard, our results demonstrate that
Fig. 3. Inﬂammasome signaling is not required for DNA damage-induced cell death of DLD-1 cells. (A) ASC-deﬁcient or ASC-expressing DLD-1 cells were treated with
etoposide (75 lM), camptothecin (CPT, 2 lM), or doxorubicin (1.5 lM) for 28 h, and the culture supernatants or cellular lysates were immunoblotted with the indicated
antibodies. (B) DLD-1 cells or PMA-primed THP-1 cells were treated with LPS (0.5 lg/ml, 4 h) and nigericin (10 lM, 1 h), or transfected with poly (dA:dT) (1 lg, 6 h). Culture
supernatants or lysates were immunoblotted with the indicated antibodies, or assayed for LDH release. (C) DLD-1-ASC cells were treated with etoposide (100 lM, 24 h) and
stained with an anti-ASC antibody. Immunoﬂuorescence was then detected as described in Section 2.
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in DLD-1-ASC or HT-29 cells.3.6. Etoposide promotes necrotic cell death in ASC-expressing
colorectal cancer cells
Then, to examine whether etoposide could trigger necrotic cell
death in DLD-1-ASC cells, we employed necrostatin-1 (Nec-1), a
selective inhibitor of RIP1 kinase to prevent RIP1-dependent necro-
sis. Unlike zVAD, Nec-1 signiﬁcantly attenuated etoposide-medi-
ated cell death in DLD-1-ASC cells (Fig. 4D, left panel). In HT-29
cells, Nec-1 also showed a signiﬁcant inhibition of etoposide-in-
duced cell death, whereas zVAD failed to protect cell death from
etoposide toxicity (Fig. 4D, right panel). As expected, Nec-1 effec-
tively prevented TCZ-induced necrotic cell death of HT-29 cells
(Fig. 4D, right panel). These observations collectively indicate that
RIP1-dependent pathway possibly contributes to the etoposide-
mediated cell death of ASC-expressing tumor cells.
We, then, examined the other features of necrotic cell death in
ASC-expressing colorectal cancer cells under DNA damage toxicity.
Cells undergoing necrosis or secondary necrosis from apoptosis re-
lease several endogenous molecules, called danger signals, such as
ATP, heat shock proteins and high mobility group box 1 protein
(HMGB1), leading to local inﬂammatory responses [30]. Etoposide,
indeed, promoted the release of ATP in DLD-1-ASC cells, and the
ATP release was signiﬁcantly prevented by Nec-1, but not by zVAD
(Fig. 4E), indicating that etoposide-mediated ATP release is cas-
pase-independent. Interestingly, DLD-1-puro cells also secreted
substantial amount of ATP responding to etoposide, but this ATP
release was less than DLD-1-ASC cells and was not signiﬁcantlyinhibited by Nec-1 (Supplementary Fig. 2A). In addition to ATP,
HMGB1 release was also detected by etoposide or TCZ stimulation,
but not by TC treatment in HT-29 cells (Fig. 4F and Supplementary
Fig. 2B), indicating that HMGB1 release is necrosis-speciﬁc in
our experiment. Indeed, etoposide-mediated HMGB1 release was
partially inhibited by Nec-1, but not by zVAD (Fig. 4F). Taken to-
gether, our data suggest that etoposide could potentiate caspase-
independent necrotic cell death in ASC-expressing colorectal
cancer cells.3.7. Mitochondrial ROS and JNK is implicated in the increased
susceptibility of ASC-expressing DLD-1 cells to DNA damaging agent
Based on the above-mentioned results, caspase-independent
necrototic pathway is likely to contribute to the etoposide-induced
cell death of ASC-expressing DLD-1 or HT-29 cells. Necrotic cell
death is often characterized by the following features: plasma
membrane rupture, mitochondrial dysfunction and swelling, en-
hanced mitochondrial ROS generation, and ATP depletion [31]. To
compare the etoposide-mediated production of mitochondrial
ROS between DLD-1-puro and DLD-1-ASC cells, we measured the
mitochondrial ROS by MitoSox staining. Compared to DLD-1-puro
cells, DLD-1-ASC cells produced higher amounts of mitochondrial
ROS after etoposide stimulation (Fig. 5A and Supplementary
Fig. 3A).
Next, to assess the sensitivity of DLD-1-puro and DLD-1-ASC
cells to cellular ROS, we added H2O2 to ASC-null or ASC-expressing
DLD-1 cell cultures. Remarkably, H2O2 had a higher cytotoxic effect
on DLD-1-ASC cells than on DLD-1-puro cells (Supplementary
Fig. 3B). These observations provide biochemical evidence that
A B
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Fig. 4. Etoposide-induced cell death of ASC-expressing colorectal cancer cells is caspase-independent. (A) DLD-1-puro or DLD-1-ASC cells were treated with etoposide
(75 lM, 24 h) and assayed for annexin V/PI staining by ﬂow cytometry. (B) DLD-1 cells with or without 5-AD priming, DLD-1-puro, and DLD-1-ASC cells were treated with
zVAD or YVAD (20 lM, 30 min), followed by treatment with etoposide (50 lM) for 38 h, as indicated. Cell survival was measured by MTT assay. (C) To determine cell survival
rate, HT-29 cells were treated with etoposide (100 lM, 36 h) in the presence of zVAD (20 lM, 30 min pretreat), or treated with TNF-a (30 ng/ml, 16 h) after pretreatment with
CHX (10 lg/ml) or zVAD (20 lM) for 30 min, as indicated. TC indicates TNF-a plus CHX. For immunoblotting, HT-29 cells were treated with etoposide (100 lM, 24 h) or TNF-a
(30 ng/ml, 16 h) after pretreatment with zVAD (20 lM) or cycloheximide (10 lg/ml) for 30 min, as indicated. (D) DLD-1-ASC cells were pretreated with Nec-1 (40 lM) or
zVAD (20 lM) for 30 min, and treated with etoposide (100 lM) for 31 h. LDH release was then assayed for determining cell death. Asterisk indicates the signiﬁcant difference
compared to only etoposide-treated cells (n = 4, p < 0.005, left panel). HT-29 cells were pretreated with Nec-1 (40 lM, 30 min) and treated with etoposide (100 lM, 36 h), or
pretreated with zVAD (20 lM) or cycloheximide (10 lg/ml) for 30 min, and then treated with TNF-a (30 ng/ml, 16 h). Asterisks indicate the signiﬁcant differences compared
to etoposide- and TCZ-treated cells, respectively (n = 3, p < 0.05; p < 0.001, right panel). (E) DLD-1-ASC cells were treated as described in (D), and cultural supernatants were
assayed for ATP release. Asterisk indicates the signiﬁcant difference from etoposide-treated cells (n = 4, p < 0.05). (F) HT-29 cells were treated as similar as described in (D),
and cultural supernatants or lysates were immunoblotted as indicated.
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agent-induced production of mitochondrial ROS and sensitizes
the cells to ROS toxicity. Then, we examined whether ROS scaven-
ger could prevent etoposide-mediated cell death in ASC-expressing
tumor cells. NAC, a well-studied antioxidant, effectively protected
DLD-1-ASC cells against H2O2-induced cytotoxicity (Supplemen-
tary Fig. 3C). Similarly, NAC signiﬁcantly reduced the etoposide-
mediated cell death in DLD-1-ASC and HT-29 cells (Fig. 5B).
Chemotherapeutic agents, including etoposide, have been
known to activate MAPKs that contribute to cell death [32]. To
examine whether MAPKs such as p38 MAPK and JNK are impli-
cated in etoposide-mediated cell death of ASC-expressing colorec-
tal cancer cells, we ﬁrst observed the activation of both kinases by
DNA damaging agents. DNA damaging agents including etoposide
or camptothecin promoted stronger phosphorylation of JNK in 5-
AD-primed DLD-1 cells expressing ASC than in unprimed DLD-1
cells (Fig. 5C, upper panel and Supplementary Fig. 4A, left panel).
In addition, ASC-deﬁcient macrophages showed attenuated JNK
phosphorylation upon treatment with etoposide (Supplementary
Fig. 4A, right panel), demonstrating that ASC facilitates etopo-side-mediated JNK activation by unknown mechanism. To support
these ﬁndings, knockdown of ASC decreased etoposide-mediated
JNK activity as determined by the phosphorylation of c-Jun in
HT-29 cells (Fig. 5C, middle panel). On the contrary, etoposide
did not activate p38 MAPK in HT-29 cells (Fig. 5C, lower panel)
and in ASC-null or ASC-expressing DLD-1 cells (Supplementary
Fig. 4B).
We, then, tested speciﬁc MAPK inhibitors for their ability to
suppress etoposide-promoted cell death. SP600125, an inhibitor
of JNK, showed a partial but signiﬁcant protection against etopo-
side cytotoxicity in ASC-expressing DLD-1 cells, whereas
SB203580, a selective p38 MAPK inhibitor, failed to prevent etopo-
side-induced cell death of ASC-expressing DLD-1 cells (Fig. 5D, left
panel and Supplementary Fig. 4C). Consistently, SP600125 signiﬁ-
cantly increased cell survival against etoposide stimulation to
HT-29 cells (Fig. 5D, right panel). These results collectively demon-
strate that JNK activation might be involved in the etoposide-in-
duced cell death of ASC-expressing colorectal cancer cells.
Then, we asked whether JNK activity is required for the etopo-
side-induced production of mitochondrial ROS. Mitochondrial ROS
A B
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E
Fig. 5. Mitochondrial ROS and JNK activation is required for etoposide-induced cell death of ASC-expressing colorectal cancer cells. (A) DLD-1-puro or DLD-1-ASC cells were
treated with etoposide (100 lM) for the indicated times. Cells were stained with MitoSox and analyzed for mitochondrial ROS production by ﬂow cytometry. (B) DLD-1-ASC
cells were treated with etoposide (100 lM, 30 h) in the presence of NAC (2 mM, 30 min pretreat), and assayed for LDH release. Asterisk indicates the signiﬁcant difference
from etoposide-treated cells (n = 4, p < 0.001, left panel). HT-29 cells were treated with etoposide (100 lM, 36 h) in the presence of NAC as indicated, and assayed for LDH
release. Asterisks indicate the signiﬁcant difference from etoposide-treated cells (n = 3, p < 0.005; p < 0.001, right panel). (C) DLD-1 cells with or without 5-AD priming
(upper panel), HT-29 cells transfected with si-control or si-ASC (middle panel), and HT-29 cells pretreated with SP600125 (lower panel) were treated with etoposide or
camptothecin, as indicated. Cellular lysates were immunoblotted with the indicated antibodies. (D) DLD-1-ASC and and HT-29 cells were treated with etoposide (75 lM,
38 h) with or without the 30 min pretreatment of SB203580 (10 lM) or SP600125 (10 lM), as indicated. Cell survival was determined by MTT assay. Asterisks indicate
signiﬁcant differences in cell survival compared to only etoposide-treated cells (n = 3, p < 0.05). (E) DLD-1-ASC cells were treated with etoposide (75 lM) in the presence of
NAC (2 mM, 30 min pretreat) for the indicated times. Cellular lysates were immunoblotted with the indicated antibodies.
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by the pretreatment of the JNK inhibitor, SP600125 (Supplemen-
tary Fig. 4D), suggesting that mitochondrial ROS production is an
independent or upstream process of the JNK signaling pathway.
Then, we checked the effect of NAC on the activation of JNK. Scav-
enging of ROS by NAC showed a partial inhibitory effect on the
phosphorylation of c-Jun (Fig. 5E). This observation suggests that
ROS, more produced in ASC-expressing cells, might positively mod-
ulate etoposide-mediated JNK activation leading to cell death. Ta-
ken together, our data demonstrate that ASC potentiates
genotoxic stress-induced cell death of colorectal cancer cells via
mitochondrial ROS production and JNK activation.4. Discussion
Inﬂammasome is a cytoplasmic multiprotein complex, which is
assembled and activated upon sensing of a microbial infection or a
danger signal derived from tissue injury [3]. To our knowledge,
inﬂammasome has been mainly studied in myeloid cells, because
the major function of inﬂammasome signaling is the maturation
and secretion of proinﬂammatory cytokines IL-1b and IL-18, which
results in triggering local inﬂammation. However, emerging evi-dences have demonstrated that inﬂammasome is implicated in
the progression of several chronic or metabolic diseases including
carcinogenesis, type II diabetes, and atherosclerosis [33,34]. It is
thus of interest to investigate the function of the inﬂammasome
in nonmyeloid cells.
The physiological role of inﬂammasome signaling in tumorigen-
esis is still controversial. Activation of the inﬂammasome induces
caspase-1-dependent pyroptotic cell death, resulting in the re-
moval of tumorigenic cells, particularly in the colon [6]. Indeed,
caspase-1-deﬁcient mice exhibit enhanced tumor formation in a
colorectal cancer model and decreased apoptosis in colonic epithe-
lial cells [35,36]. This tumor-suppressive role of the inﬂammasome
is supported by the ﬁnding that Nlrp3/, ASC/, and caspase-1/
mice are more susceptible to colitis-associated colorectal cancer
than wild-type mice [35–37]. In contrast, it is also reported that
Nlrp3/ and caspase-1/ mice showed less severe dextran sulfate
sodium-induced colitis [38,39]. Therefore, the contribution of the
inﬂammasome to tumor suppression or progression is debatable
based on the context and remains to be clariﬁed.
The inﬂammasome adaptor molecule, ASC, seems more directly
implicated in the regulation of tumorigenesis, because it is found
to be epigenetically silenced with a high frequency in many cancer
cells [8–10]. Overexpression or ligand-induced oligomerization of
190 S. Hong et al. / Cancer Letters 331 (2013) 183–191ASC clearly makes nontumorigenic cells susceptible to apoptotic
stimuli [12]. Interestingly, in MCF-7 cells upon genotoxic stress,
ASC is upregulated and localized to the mitochondria in a p53-
dependent manner, leading to mitochondria-mediated apoptosis
[16]. However, it has not been examined in detail whether restora-
tion of ASC expression in epigenetically ASC-silenced cancer cells
facilitates cell death in response to chemotherapeutic agents. In
the present study, we demonstrated the putative tumor-suppres-
sive effect of ASC expression in human colorectal cancer cells,
DLD-1. Given that DLD-1 cells lack wild-type p53 [40], DNA dam-
aging agents might trigger p53-independent cell death in DLD-1
cells. Moreover, we found no difference in the DNA damage re-
sponse between ASC-deﬁcient and ASC-expressing DLD-1 cells, as
determined by the phosphorylation of H2AX (Supplementary
Fig. 5A).
According to a recent report, ASC was able to induce not only
apoptotic, but also necrotic cell death, depending on the cellular
context [41]. After being activated by the upstream recombinant
Nod-like receptor family protein, ASC induces apoptosis in cas-
pase-1-deﬁcient cells, but necrotic cell death in caspase-1-express-
ing cells, regardless of caspase-1 activity [41]. ASC is thus likely to
promote necrotic cell death in DLD-1-ASC or HT-29 cells due to an
expression of caspase-1 in both cells (Supplementary Fig. 5B),
although the precise mechanism as to how caspase-1 controls
the type of cell death is not clear. Further study will be needed
to clarify how ASC contributes to the progression of apoptotic or
necrotic cell death under the different cellular context.
In conclusion, ASC expression clearly promotes colorectal can-
cer cell death in response to genotoxic stress. This ﬁnding suggests
that ASC possesses a tumor-suppressive function, and that its
expression might be epigenetically silenced during carcinogenesis
in several ASC-deﬁcient cancer cells, such as DLD-1. ASC is able to
trigger apoptotic cell death; however, in our study, it also induced
necrotic cell death through the production of mitochondrial ROS
and through the activation of JNK signaling upon stimulation with
a chemotherapeutic agent. As the epigenetic regulation of ASC
expression is deﬁnitively correlated with the colorectal carcino-
genesis, methylation status of ASC gene could be used for cancer
prognosis. Furthermore, the restoration of ASC expression by
demethylating agents could be a potent strategy to enhance the
efﬁcacy of chemotherapeutic drugs in ASC-silenced cancer
patients.
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